Management of hypertrophic cardiomyopathy.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
17 Apr 2024
17 Apr 2024
Historique:
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
Hypertrophic cardiomyopathy is an important cause of heart failure and arrhythmias, including sudden death, with a major impact on the healthcare system. Genetic causes and different phenotypes are now increasingly being identified for this condition. In addition, specific medications, such as myosin inhibitors, have been recently shown as potentially able to modify its symptoms, hemodynamic abnormalities and clinical course. Our article aims to provide a comprehensive outline of the epidemiology, diagnosis and treatment of hypertrophic cardiomyopathy in the current era.
Identifiants
pubmed: 38625835
doi: 10.2459/JCM.0000000000001616
pii: 01244665-990000000-00206
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35:2733–2779.
Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Heart Failure and Cardiomyopathy Chinese guidelines on the management of hypertrophic cardiomyopathy 2017. Chin J Heart Fail Cardiomyopathy 2017; 1:65–86.
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2020; 76:3022–3055.
Kitaoka H, Tsutsui H, Kubo T, et al. Japanese Circulation Society Joint Working Group JCS/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. Circ J 2021; 85:1590–1689.
Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958; 20:1–8.
Brent LB, Aburano A, Fisher DL, et al. Familial muscular subaortic stenosis: an unrecognized form of ‘idiopathic heart diseases,’ with clinical and autopsy observation. Circulation 1960; 21:167–180.
Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg 1961; 154:181–189.
Braunwald E, Aygen MM. Idiopathic myocardial hypertrophy without congestive heart failure or obstruction to blood flow: clinical, hemodynamic and angiocardiographic studies in fourteen patients. Am J Med 1963; 35:7–19.
Liew AC, Vassiliou VS, Cooper R, et al. Hypertrophic cardiomyopathy: past, present and future. J Clin Med 2017; 6:118.
Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121:749–770.
Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2022; 79:372–389.
Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2022; 79:390–414.
Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study: coronary artery risk development in (young) adults. Circulation 1995; 92:785–789.
Maron BJ, Mathenge R, Casey SA, et al. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 1999; 33:1590–1595.
Maron BJ, Spirito P, Roman MJ, et al. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51-77 years (the strong heart study). Am J Cardiol 2004; 93:1510–1514.
Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8 080 adults. Am J Med 2004; 116:14–18.
Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet 2012; 91:513–519.
Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J 2010; 31:1551–1553.
Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009; 54:220–228.
Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2012; 14:13.
Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65:1249–1254.
Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic cardiomyopathy. JACC Heart Fail 2018; 6:376–378.
Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990; 62:999–1006.
Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 2012; 9:57–63.
Ingles J, Burns C, Bagnall RD, et al. Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications. Circ Cardiovasc Genet 2017; 10:e001620.
Geske JB, Sorajja P, Ommen SR, et al. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv 2011; 4:704–709.
Ayoub C, Geske JB, Larsen CM, et al. Comparison of valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy. Am J Cardiol 2017; 120:2265–2271.
Reant P, Dufour M, Peyrou J, et al. Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study. Eur Heart J Cardiovasc Imaging 2018; 19:31–38.
Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348:295–303.
Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27:1933–1941.
Avegliano G, Politi MT, Costabel JP, et al. Differences in the extent of fibrosis in obstructive and nonobstructive hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown) 2019; 20:389–396.
Sherrid MV, Balaram S, Kim B, et al. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. J Am Coll Cardiol 2016; 67:1846–1858.
Raphael CE, Cooper R, Parker KH, et al. Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance. J Am Coll Cardiol 2016; 68:1651–1660.
Ciampi Q, Olivotto I, Peteiro J, et al. Prognostic value of reduced heart rate reserve during exercise in hypertrophic cardiomyopathy. J Clin Med 2021; 10:1347.
Olivotto I, Maron BJ, Montereggi A, et al. Prognostic valueof systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33:2044–2051.
Ranthe MF, Carstensen L, Øyen N, et al. Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons. Circulation 2015; 132:1013–1019.
Williams L, Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. Europace 2007; 9:817–822.
Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009; 119:1703–1710.
Nagueh SF, Phelan D, Abraham T, et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2022; 35:533–569.
Finocchiaro G, Sheikh N, Biagini E, et al. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm 2020; 17:142–151.
Monzo L, Martino A, Lanzillo C, et al. Electrocardiographic voltage criteria in patients with hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown) 2020; 21:696–703.
Tiron C, Ramos R, Iglesies J, et al. The Peguero-Lo Presti ECG criteria improve diagnostic accuracy of left ventricular hypertrophy in hypertrophic cardiomyopathy patients. J Cardiovasc Med (Hagerstown) 2021; 22:946–947.
McLeod CJ, Ackerman MJ, Nishimura RA, et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol 2009; 54:229–233.
Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45:697–704.
Monserrat L, Elliott PM, Gimeno JR, et al. Nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42:873–879.
Wang W, Lian Z, Rowin EJ, et al. Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2017; 10:e004604.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28:1–39.
Echocardiography Group of Chinese Society of Echocardiography of Chinese Medical Association Guideline on the echocardiographic measurements in Chinese adults. Chinese J Ultrasonogr 2016; 25:645–666.
Haland TF, Edvardsen T. The role of echocardiography in management of hypertrophic cardiomyopathy. J Echocardiogr 2020; 18:77–85.
Geske JB, McKie PM, Ommen SR, et al. B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. J Am Coll Cardiol 2013; 61:2456–2460.
Coats CJ, Gallagher MJ, Foley M, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J 2013; 34:2529–2537.
Zhang C, Liu R, Yuan J, et al. Significance and determinants of cardiac troponin I in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 2015; 116:1744–1751.
Gommans DHF, Cramer GE, Fouraux MA, et al. Usefulness of high-sensitivity cardiac troponin T to predict long-term outcome in patients with hypertrophic cardiomyopathy. Am J Cardiol 2021; 152:120–124.
Chinese Society of Cardiology of Chinese Medical Association, Chinese College of Cardiovascular Physician of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology Chinese expert consensus on clinical application of magnetic resonance imaging in cardiomyopathy. Chin J Cardiol 2015; 43:673–681.
Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014; 130:484–495.
Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late gadolinum enhancement in patients with hypertrophic cardiomypathy and preserved systolic function. J Am Coll Cardiol 2018; 72:857–870.
Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm 2022; 19:e1–e60.
Ahluwalia M, Ho CY. Cardiovascular genetics: the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy. Heart 2021; 107:183–189.
Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 2018; 138:1387–1398.
Mathew J, Zahavich L, Lafreniere-Roula M, et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. Clin Genet 2018; 93:310–319.
Mogensen J, van Tintelen JP, Fokstuen S, et al. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. Eur Heart J 2015; 36:1367–1370.
Spracklen TF, Keavney B, Laing N, et al. Modern genomic techniques in the identification of genetic causes of cardiomyopathy. Heart 2022; 108:1843–1850.
Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405–424.
Deignan JL, Chung WK, Kearney HM, et al. ACMG Laboratory Quality Assurance Committee Points toconsider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2019; 21:1267–1270.
Bayonas-Ruiz A, Muñoz-Franco FM, Ferrer V, et al. Cardiopulmonary exercise test in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. J Clin Med 2021; 10:2312.
Seferović PM, Tsutsui H, McNamara DM, et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position Statement on endomyocardial biopsy. Eur J Heart Fail 2021; 23:854–871.
Guo X, Fan C, Wang H, et al. The prevalence and long-term outcomes of extreme right versus extreme left ventricular hypertrophic cardiomyopathy. Cardiology 2016; 133:35–43.
Bombard Y, Brothers KB, Fitzgerald-Butt S, et al. The responsibility to recontact research participants after reinterpretation of genetic and genomic research results. Am J Hum Genet 2019; 104:578–595.
van Velzen HG, Schinkel AFL, Baart SJ, et al. Outcomes of contemporary family screening in hypertrophic cardiomyopathy. Circ Genom Precis Med 2018; 11:e001896.
Lorenzini M, Norrish G, Field E, et al. Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers. J Am Coll Cardiol 2020; 76:550–559.
Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol 2011; 107:604–608.
Williams LK, Misurka J, Ho CY, et al. Multilayer myocardial mechanics in genotype-positive left ventricular hypertrophy-negative patients with hypertrophic cardiomyopathy. Am J Cardiol 2018; 122:1754–1760.
Maurizi N, Michels M, Rowin EJ, et al. Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy. Circulation 2019; 139:830–833.
Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114:2232–2239.
Hughes RK, Knott KD, Malcolmson J, et al. Apical hypertrophic cardiomyopathy: the variant less known. J Am Heart Assoc 2020; 9:e015294.
Efthimiadis GK, Pagourelias ED, Parcharidou D, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circ J 2013; 77:2366–2374.
Olivotto I, Cecchi F, Poggesi C, et al. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 2012; 5:535–546.
Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114:216–225.
Biagini E, Coccolo F, Ferlito M, et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005; 46:1543–1550.
Thaman R, Gimeno JR, Murphy RT, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 2005; 91:920–925.
Kawarai H, Kajimoto K, Minami Y, et al. Risk of sudden death in end-stage hypertrophic cardiomyopathy. J Card Fail 2011; 17:459–464.
Xiao Y, Yang KQ, Yang YK, et al. Clinical characteristics and prognosis of end-stage hypertrophic cardiomyopathy. Chin Med J (Engl) 2015; 128:1483–1489.
Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. J Am Coll Cardiol 2020; 75:3033–3043.
Kubo T, Gimeno JR, Bahl A, et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 2007; 49:2419–2426.
Biagini E, Spirito P, Rocchi G, et al. Prognostic implication of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol 2009; 104:1727–1731.
De Bortoli M, Vio R, Basso C, et al. Novel missense variant in MYL2 gene associated with hypertrophic cardiomyopathy showing high incidence of restrictive physiology. Circ Genom Precis Med 2020; 13:e002824.
Siontis KC, Geske JB, Ong K, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc 2014; 3:e001002.
Guttmann OP, Rahman MS, O′Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014; 100:465–472.
Rowin EJ, Hausvater A, Link MS, et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 2017; 136:2420–2436. doi:10.1161/CIRCULATIONAHA.117.029267.
doi: 10.1161/CIRCULATIONAHA.117.029267
Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definitioand classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021; 23:352–380.
Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol 2017; 69:761–773.
Yang K, Song YY, Chen XY, et al. Apical hypertrophic cardiomyopathy with left ventricular apical aneurysm: prevalence, cardiac magnetic resonance characteristics, and prognosis. Eur Heart J Cardiovasc Imaging 2020; 21:1341–1350.
Cui L, Tse G, Zhao Z, et al. Mid-ventricular obstructive hypertrophic cardiomyopathy with apical aneurysm: an important subtype of arrhythmogenic cardiomyopathy. Ann Noninvasive Electrocardiol 2019; 24:e12638.
Lee DZJ, Montazeri M, Bataiosu R, et al. Clinical characteristics and prognostic importance of left ventricular apical aneurysms in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2022; 15:1696–1711.
Hamada M. Left ventricular thrombus in hypertrophic cardiomyopathy. Intern Med 2019; 58:465–467.
Lodi E, Lucio D, Federica F, et al. Hypertrophic-phenotype cardiopathy: the great simulator. J Cardiovasc Med (Hagerstown) 2022; 23:748–751.
Autore C, Bariani R, Bauce B, et al. From the phenotype to precision medicine: an update on the cardiomyopathies diagnostic workflow. J Cardiovasc Med (Hagerstown) 2023; 24: (Suppl 2): e178–e186.
Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res 2023; 118:3517–3535.
Merlo M, Pagura L, Porcari A, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail 2022; 24:1377–1386.
Fontana M, Ćorović A, Scully P, et al. Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging 2019; 12 (11 Pt 2):2345–2356.
Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133:2404–2412.
Joury A, Gupta T, Krim SR. Cardiac amyloidosis: presentations, diagnostic work-up and collaborative approach for comprehensive clinical management. Curr Prol Cardiol 2021; 46:100910.
Expert consensus for diagnosis and treatment of Fabry disease in China (2021). Chin J Intern Med 2021; 60:321–330.
Lotan D, Salazar-Mendiguchía J, Mogensen J, et al. Clinical profile of cardiac involvement in Danon disease: a multicenter European Registry. Circ Genom Precis Med 2020; 13:e003117.
Porto AG, Brun F, Severini GM, et al. Clinical spectrum of PRKAG2 syndrome. Circ Arrhythm Electrophysiol 2016; 9:e003121.
Cook A, Giunti P. Friedreich's ataxia: clinical features, pathogenesis and management. Br Med Bull 2017; 124:19–30.
Roberts AE, Allanson JE, Tartaglia M, et al. Noonan syndrome. Lancet 2013; 381:333–342.
Martínez-Quintana E, Rodríguez-González F. LEOPARD syndrome: clinical features and gene mutations. Mol Syndromol 2012; 3:145–157.
Aoki Y, Niihori T, Inoue S, et al. Recent advances in RASopathies. J Hum Genet 2016; 61:33–39.
Ng YS, Bindoff LA, Gorman GS, et al. Mitochondrial disease in adults: recent advances and future promise. Lancet Neurol 2021; 20:573–584.
Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized trial of metoprolol in patients with obstructive hypertropic cardiomyopathy. J Am Coll Cardiol 2021; 78:2505–2517.
Dybro AM, Rasmussen TB, Nielsen RR, et al. Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2022; 79:1565–1575.
Monda E, Lioncino M, Palmiero G, et al. Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy: the BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study. Int J Cardiol 2022; 354:22–28.
Zampieri M, Argirò A, Marchi A, et al. Mavacamten, a novel therapeutic strategy for obstructive hypertrophic cardiomyopathy. Curr Cardiol Rep 2021; 23:79.
Olivotto I, Oreziak A, Barriales-Villa R, et al. EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020; 396:759–769.
Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397:2467–2475.
Hegde SM, Lester SJ, Solomon SD, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertensive cardiomyopathy. J Am Coll Cardiol 2021; 78:2518–2532.
Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol 2022; 80:95–108.
Desai MY, Owens AT, Geske JB, et al. Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: outcomes through 32-weeks. Circulation 2023; 147:850–863.
Cremer PC, Geske JB, Owens A, et al. Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM Study. Circ Cardiovasc Imaging 2022; 15:e014986.
Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2020; 75:2649–2660.
Arbelo E, Protonotarios A, Gimeno JR, et al. ESC Scientific Document Group 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023; ehad194 online ahead of print.
Chuang C, Collibee S, Ashcraft L, et al. Discovery of Aficamten (CK-274), a next generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem 2021; 64:14142–14152.
Masri A, Olivotto I. Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter. J Am Heart Assoc 2022; 11:e024656.
Maron MS, Masri A, Choudhury L, et al. REDWOOD-HCM Steering Committee and Investigators. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2023; 81:34–45.
Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with (-blockade or verapamil. Circ Heart Fail 2013; 6:694–702.
Adler A, Fourey D, Weissler-Snir A, et al. Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients. J Am Heart Assoc 2017; 6:e005152.
Coppini R, Ferrantini C, Pioner JM, et al. Electrophysiological and contractile effects of disopyramide in patients with obstructive hypertrophic cardiomyopathy: a translational study. JACC Basic Transl Sci 2019; 4:795–813.
Hamada M, Ikeda S, Ohshima K, et al. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy. J Cardiol 2016; 67:279–286.
Maron BJ, Dearani JA, Smedira NG, et al. Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC Expert Panel. Am J Cardiol 2022; 180:124–139.
Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:470–476.
Wang S, Luo M, Sun H, et al. A retrospective clinical study of transaortic extended septal myectomy for obstructive hypertrophic cardiomyopathy in China. Eur J Cardiothorac Surg 2013; 43:534–540.
Maron BJ, Dearani JA, Ommen SR, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol 2015; 66:1307–1308.
Wang S, Cui H, Yu Q, et al. Excision of anomalous muscle bundles as an important addition to extended septal myectomy for treatment of left ventricular outflow tract obstruction. J Thorac Cardiovasc Surg 2016; 152:461–468.
Maron MS, Rastegar H, Dolan N, et al. Outcomes over follow-up ≥ 10 years after surgical myectomy for symptomatic obstructive hypertrophic cardiomyopathy. Am J Cardiol 2022; 163:91–97.
Holst KA, Hanson KT, Ommen SR, et al. Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery. Mayo Clin Proc 2019; 94:66–73.
Yang Q, Zhu C, Cui H, et al. Surgical septal myectomy outcome for obstructive hypertrophic cardiomyopathy after alcohol septal ablation. J Thorac Dis 2021; 13:1055–1065.
Rudenko KV, Lazoryshynets VV, Nevmerzhytska LO, et al. Septal myectomy with mitral valve surgery in patients after alcohol septal ablation. Interact Cardiovasc Thorac Surg 2022; 34:723–730.
Lio A, D’Ovidio M, Chirichilli I, et al. Extended septal myectomy for obstructive hypertrophic cardiomyopathy and its impact on mitral valve function. J Cardiovasc Med (Hagerstown) 2024; 25:210–217.
Nishimura RA, Seggewiss H, Schaff HV. Hypertrophic obstructive cardiomyopathy: surgical myectomy and septal Ablation. Circ Res 2017; 121:771–783.
Nguyen A, Schaff HV. Surgical myectomy: subaortic, midventricular, and apical. Cardiol Clin 2019; 37:95–104.
Schaff HV, Brown ML, Dearani JA, et al. Apical myectomy: a new surgical technique for management of severely symptomatic patients with apical hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 2010; 139:634–640.
Hang D, Schaff HV, Ommen SR, et al. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 2018; 155:2096–2102.
China Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology, Group of Septal Ablation Treatment of Hypertrophic Obstructive Cardiomyopathy Chinese expert consensus for septal myocardial ablation of hypertrophic obstructive cardiomyopathy. Chin J Cardiol 2011; 39:886–891.
Veselka J, Faber L, Liebregts M, et al. Long-term outcome of repeated septal reduction therapy after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: insight from the Euro-ASA registry. Arch Med Sci 2020; 16:1239–1242.
Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J 2016; 37:1517–1523.
Batzner A, Pfeiffer B, Neugebauer A, et al. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2018; 72:3087–3094.
Nguyen A, Schaff HV, Hang D, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort. J Thorac Cardiovasc Surg 2019; 157:306–315.
Nguyen A, Schaff HV, Hang D, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort. J Thorac Cardiovasc Surg 2019; 157:306–315. e3.
Faber L, Welge D, Fassbender D, et al. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol 2007; 119:163–167.
Veselka J, Jensen M, Liebregts M, et al. Alcohol septal ablation in patients with severe septal hypertrophy. Heart 2020; 106:462–466.
Cui H, Schaff HV, Wang S, et al. Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2022; 79:1647–1655.
Liu L, Li J, Zuo L, Zhang J, et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2018; 72:1898–1909.
Zhou M, Ta S, Hahn RT, et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy. JAMA Cardiol 2022; 7:529–538.
Lawrenz T, Kuhn H. Endocardial radiofrequency ablation of septal hypertrophy: a new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy. Z Kardiol 2004; 93:493–499.
Lawrenz T, Lawin D, Radke K, et al. Acute and chronic effects of endocardial radiofrequency ablation of septal hypertrophy in HOCM. J Cardiovasc Electrophysiol 2021; 32:2617–2624.
McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599–3726.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145:e876–e894.
Mehra MR, Canter CE, Hannan MM, et al. International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016; 35:1–23.
Guttmann OP, Pavlou M, O’Mahony C, et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail 2015; 17:837–845.
Jung H, Yang PS, Jang E, et al. Effectiveness and safety of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study. Chest 2019; 155:354–363.
Providencia R, Elliott P, Patel K, et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart 2016; 102:1533–1543.
Bogachev-Prokophiev AV, Afanasyev AV, Zheleznev SI, et al. Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg 2018; 155:1536–1542. e2.
Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Heart Rhythm 2016; 13:1552–1559.
O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014; 35:2010–2020.
Buongiorno AL, Blandino A, Bianchi F, et al. Effectiveness of 2014 ESC HCM-Risk-SCD score in prediction of appropriate implantable-cardioverter-defibrillator shocks. J Cardiovasc Med (Hagerstown) 2023; 24:313–314.
Maron MS, Rowin EJ, Wessler BS, et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol 2019; 4:644–657.
Norrish G, Ding T, Field E, et al. Development a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids). JAMA Cardiol 2019; 4:918–927.
Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 2020; 142:217–229.
Maron BJ, Nishimura RA, Maron MS. Shared decision-making in HCM. Nat Rev Cardiol 2017; 14:125–126.
Saberi S. Hypertrophic cardiomyopathy in pregnancy. Cardiol Clin 2021; 39:143–150.
Pelliccia A, Sharma S, Gati S, Bäck M, et al. ESC Scientific Document Group 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021; 42:17–96.
Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018; 379:655–668.